Home
VIGL
VIGL News

Latest Vigil Neuroscience Inc. (VIGL) News on June 10, 2025

MT Newswires

6 days ago

Vigil Neuroscience Discontinues Phase 2 Extension Study of Iluzanebart in ALSP

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

GlobeNewswire

6 days ago

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

Zacks

8 days ago

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

MT Newswires

13 days ago

Stifel Downgrades Vigil Neuroscience to Hold From Buy, Adjusts Price Target to $8 From $11

MT Newswires

14 days ago

HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8

Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade

Zacks

18 days ago

Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade

Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

Zacks

18 days ago

Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

MT Newswires

18 days ago

Mizuho Downgrades Vigil Neuroscience to Neutral From Outperform, Cuts Price Target to $8 From $13

Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

TipRanks

18 days ago

Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

MT Newswires

19 days ago

Top Midday Gainers

Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

Pharmaceutical Technology

19 days ago

Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

Investopedia

19 days ago

Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout

Zacks

19 days ago

Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Investor's Business Daily

19 days ago

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

MT Newswires

19 days ago

Guggenheim Downgrades Vigil Neuroscience to Neutral From Buy, Adjusts Price Target to $8 From $16

MT Newswires

19 days ago

William Blair Downgrades Vigil Neuroscience to Market Perform From Outperform

MT Newswires

19 days ago

Wedbush Downgrades Vigil Neuroscience to Neutral From Outperform, Cuts Price Target to $8 From $13

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

Benzinga

19 days ago

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

MT Newswires

19 days ago

Sanofi to Acquire Vigil Neuroscience for Up to $600 Million

Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Insider Monkey

19 days ago

Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Investing.com

19 days ago

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play

Sanofi to Buy Vigil Neuroscience for About $470 Million

The Wall Street Journal

19 days ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

GlobeNewswire

a month ago

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

GlobeNewswire

2 months ago

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

MT Newswires

2 months ago

Vigil Neuroscience Files Secondary Stock Shelf

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

Zacks

3 months ago

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

MT Newswires

3 months ago

Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

GlobeNewswire

3 months ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

GlobeNewswire

3 months ago

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?

Simply Wall St.

3 months ago

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025

Insider Monkey

3 months ago

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire

4 months ago

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Mixed results for Keytruda; AbbVie to work with Neomorph

BioPharma Dive

5 months ago

Mixed results for Keytruda; AbbVie to work with Neomorph

MT Newswires

5 months ago

Vigil Neuroscience Shares Jump After Alzheimer's Disease Treatment Shows Favorable Safety Profile in Early Study

Benzinga

5 months ago

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

GlobeNewswire

5 months ago

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

GlobeNewswire

5 months ago

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

MT Newswires

6 months ago

William Blair Initiates Vigil Neuroscience at Outperform

Vigil Neuroscience to Present at Upcoming Investor Conferences

GlobeNewswire

7 months ago

Vigil Neuroscience to Present at Upcoming Investor Conferences

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake

Simply Wall St.

7 months ago

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

GlobeNewswire

7 months ago

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

8 months ago

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial

Clinical Trials Arena

9 months ago

FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial

MT Newswires

9 months ago

Vigil Neuroscience Says FDA Lifts Partial Hold on Phase 1 Trial of Potential Alzheimer's Drug

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

GlobeNewswire

9 months ago

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

GlobeNewswire

9 months ago

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Vigil Neuroscience to Present at Upcoming September Investor Conferences

GlobeNewswire

9 months ago

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

10 months ago

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

GlobeNewswire

10 months ago

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)

GlobeNewswire

10 months ago

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)

Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker

Benzinga

a year ago

Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

GlobeNewswire

a year ago

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

MT Newswires

a year ago

HC Wainwright Cuts Price Target on Vigil Neuroscience to $17 From $24, Maintains Buy Rating

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

GlobeNewswire

a year ago

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

GlobeNewswire

a year ago

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now?

Insider Monkey

a year ago

Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now?

MT Newswires

a year ago

Wedbush Adjusts Price Target on Vigil Neuroscience to $23 From $22 on Heels of Sanofi Investment, Maintains Outperform Rating

MT Newswires

a year ago

Top Premarket Gainers

MT Newswires

a year ago

Vigil Neuroscience Receives $40 Million Investment From Sanofi

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

GlobeNewswire

a year ago

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts

TipRanks

a year ago

These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts

Vigil Neuroscience to Present in Upcoming June Investor Conferences

GlobeNewswire

a year ago

Vigil Neuroscience to Present in Upcoming June Investor Conferences

All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

GlobeNewswire

a year ago

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

GuruFocus.com

a year ago

Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

GlobeNewswire

a year ago

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

GlobeNewswire

a year ago

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

GlobeNewswire

a year ago

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

GlobeNewswire

a year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

GlobeNewswire

a year ago

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

GlobeNewswire

a year ago

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Is It Smart To Buy FS Bancorp, Inc. (NASDAQ:FSBW) Before It Goes Ex-Dividend?

Simply Wall St.

a year ago

Is It Smart To Buy FS Bancorp, Inc. (NASDAQ:FSBW) Before It Goes Ex-Dividend?

Clough Global Opportunities Fund Section 19(a) Notice

ACCESSWIRE

a year ago

Clough Global Opportunities Fund Section 19(a) Notice

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

GlobeNewswire

a year ago

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

a year ago

18 Best 52-Week Low Stocks To Buy Now

Community West Bancshares Reports Full Year Earnings Amid Merger Developments

GuruFocus.com

a year ago

Community West Bancshares Reports Full Year Earnings Amid Merger Developments

Arbe Chipset Empowers HiRain's LRR610 4D Imaging Radar Systems Set for Mass Production by the End of 2024

PR Newswire

a year ago

Arbe Chipset Empowers HiRain's LRR610 4D Imaging Radar Systems Set for Mass Production by the End of 2024

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland

GlobeNewswire

a year ago

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland

Inogen Names Michael Bourque as New Chief Financial Officer

Business Wire

a year ago

Inogen Names Michael Bourque as New Chief Financial Officer

Loop Industries and Bormioli Pharma Unveil an Innovative Pharmaceutical Packaging Bottle Manufactured with 100% Recycled Virgin Quality Loop PET Resin at Pharmapack 2024

ACCESSWIRE

a year ago

Loop Industries and Bormioli Pharma Unveil an Innovative Pharmaceutical Packaging Bottle Manufactured with 100% Recycled Virgin Quality Loop PET Resin at Pharmapack 2024

Business Wire

a year ago

AMCON Distributing Company Announces $0.18 Quarterly Dividend

Business Wire

a year ago

Cherry Hill Mortgage Investment Corporation Announces Taxable Composition of 2023 Dividends

With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors

Amcon Distributing Co (DIT) Reports Mixed Q1 Results Amid Operational Challenges

GuruFocus.com

a year ago

Amcon Distributing Co (DIT) Reports Mixed Q1 Results Amid Operational Challenges

Business Wire

a year ago

Evans Bancorp Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Business Wire

a year ago

AMCON Distributing Company Reports Results for the Quarter Ended December 31, 2023

FiscalNote to Present at the 26th Annual Needham Growth Conference

Business Wire

a year ago

FiscalNote to Present at the 26th Annual Needham Growth Conference

Loop Industries Announces MOU For US$66 Million of Non-Dilutive Financing from Reed Management, as Part of a Joint Venture for European Infinite Loop(TM) Technology Roll-Out

ACCESSWIRE

a year ago

Loop Industries Announces MOU For US$66 Million of Non-Dilutive Financing from Reed Management, as Part of a Joint Venture for European Infinite Loop(TM) Technology Roll-Out

Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?

Zacks

a year ago

Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?

Mondee to Participate in 26th Annual Needham Growth Conference

GlobeNewswire

a year ago

Mondee to Participate in 26th Annual Needham Growth Conference

Canadian Investment Regulatory Organization Trading Halt - MMED.WR

CNW Group

a year ago

Canadian Investment Regulatory Organization Trading Halt - MMED.WR

Atlas Lithium Intersects Wide, High-Grade Lithium Mineralization, Continues Expansion of "Anitta 3" and "Anitta 4" Pegmatites

Newsfile

a year ago

Atlas Lithium Intersects Wide, High-Grade Lithium Mineralization, Continues Expansion of "Anitta 3" and "Anitta 4" Pegmatites

Morgan Stanley Initiates Research Coverage on Mondee

GlobeNewswire

a year ago

Morgan Stanley Initiates Research Coverage on Mondee

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

GlobeNewswire

a year ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

USCB Financial Holdings, Inc. To Announce Fourth Quarter 2023 Results

GlobeNewswire

a year ago

USCB Financial Holdings, Inc. To Announce Fourth Quarter 2023 Results

Share on Social Networks: